Recent advances in molecularly targeted therapy in advanced renal cell carcinoma

Jenny J. Kim, Brian I. Rini

Research output: Contribution to journalReview articlepeer-review

Abstract

In the last few years, enhanced understanding of the biology of clear cell renal cell carcinoma has led to the development of molecular signaling inhibitors, which, with their superior anti-tumor activity demonstrated in randomized clinical trials, have led to a paradigm shift in the treatment of advanced renal cell carcinoma from cytokine-based therapy to signaling-inhibitor therapy. Relevant therapeutic signaling pathways that have emerged are VEGF receptor and mammalian target of rapamycin pathways, and signaling inhibitors sunitinib, sorafenib, temsirolimus and, most recently, everolimus are approved by the FDA for treatment of advanced renal cell carcinoma in the USA. Newer agents with promising anti-tumor activity are in continued development, as are efforts to uncover additional therapeutic targets. Currently, the optimal use of available agents, such as sequence and combination strategies, as well as their role in the adjuvant and neoadjuvant setting, remain unclear and investigative efforts are underway.

Original languageEnglish (US)
Pages (from-to)309-320
Number of pages12
JournalTherapy
Volume6
Issue number3
DOIs
StatePublished - May 1 2009

Keywords

  • Mammalian target of rapamycin
  • Monoclonal antibody
  • Renal cell carcinoma
  • Targeted therapy
  • Tyrosine kinase inhibitor
  • VEGF receptor
  • von Hippel Lindau

ASJC Scopus subject areas

  • Pharmacology (medical)

Fingerprint Dive into the research topics of 'Recent advances in molecularly targeted therapy in advanced renal cell carcinoma'. Together they form a unique fingerprint.

Cite this